ERBB2 and breast carcinoma: This is unsurprising as following RxPONDER the ASCO guidelines were updated to recommend the use of Oncotype DX testing to guide decision making regarding adjuvant chemotherapy use among postmenopausal women with ER-positive, HER2-negative, N1 breast cancer.